Search
Search Results
-
Access to essential and innovative anti-cancer medicines: a longitudinal study in Nan**g, China
PurposeTo evaluate the availability, cost, affordability of anti-cancer medicines in Nan**g, Jiangsu.
MethodsA longitudinal tracking investigation...
-
Variables affecting pricing of orphan drugs: the Italian case
Background and aimEvidence on determinants of prices for orphan medicines is scarce and not available for Italy. The aim of this paper is to provide...
-
Recovery of suspended reimbursements of high-cost drugs subjected to monitoring registries and negotiated agreements (MEAs): a tool for governance and clinical appropriateness in the Italian reality
The Monitoring Registries and negotiated agreements (MEAs) established by the Italian Medicines Agency (AIFA) exemplify a pinnacle of excellence in...
-
Tackling barriers to scale up human papillomavirus vaccination in China: progress and the way forward
The human papillomavirus (HPV) vaccine is the first vaccine developed specifically targeting the prevention of cervical cancer. For more than...
-
The role of budget impact and its relationship with cost-effectiveness in reimbursement decisions on health technologies in the Netherlands
Health authorities using cost-effectiveness analysis (CEA) for informing reimbursement decisions on health technologies increasingly require economic...
-
Price Is Right: Exploring Prescription Drug Coverage Barriers for Irritable Bowel Syndrome Using Threshold Pricing Analysis
BackgroundPrescription drug costs exert profound effects on commercial insurance coverage and access to effective therapy.
AimsWe aimed to assess...
-
The impact of reimbursement negotiations on cost and availability of new pharmaceuticals: evidence from an online experiment
BackgroundThe necessity to measure and reward “value for money” of new pharmaceuticals has become central in health policy debates, as much as the...
-
Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
BackgroundNew biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) all...
-
Ibrutinib versus bendamustine plus rituximab for first-line treatment of 65 or older patients with untreated chronic lymphocytic leukemia without del(17p)/TP53 mutation in China: a lifetime economic research study
BackgroundThe incidence and mortality rates of patients with chronic lymphocytic leukemia (CLL) in China have recently increased. This study...
-
The impact of an ‘evergreening’ strategy nearing patent expiration on the uptake of biosimilars and public healthcare costs: a case study on the introduction of a second administration form of trastuzumab in The Netherlands
In this paper, we explore dynamic market share and public healthcare costs of trastuzumab’s evergreening (subcutaneous) variant during introduction...
-
Were economic evaluations well reported for the newly listed oncology drugs in China’s national reimbursement drug list
PurposeTo assess the reporting quality of published economic evaluations of the negotiated oncology drugs listed for China’s 2020 National...
-
Market access and value-based pricing of digital health applications in Germany
In December 2019, the Digital Health Care Act (“Digitale-Versorgung-Gesetz”) introduced a general entitlement to the provision and reimbursement of...
-
Financial burden of coronary artery bypass grafting in India: implications for catastrophic health expenditure and healthcare access
Cardiovascular diseases (CVD) have become a leading cause of mortality in India. High costs of coronary artery bypass grafting (CABG) impose a...
-
A Framework for the Fair Pricing of Medicines
As high-cost medicines put increasing pressure on public health care budgets, the need to identify ‘fair’ prices for medicines has never been...
-
13-Valent pneumococcal conjugate vaccines vaccination innovative strategy in Weifang City, China: a case study
The World Health Organization (WHO) prioritizes pneumococcal disease as a vaccine-preventable disease and recommends the inclusion of pneumococcal...
-
The impact of the national volume-based procurement policy on the use of policy-related drugs in Nan**g: an interrupted time-series analysis
BackgroundIn September 2019, the “4 + 7” centralized procurement pilot program was expanded nationwide aiming at reducing drug prices by means of...
-
Price Models for Multi-indication Drugs: A Systematic Review
BackgroundMarketing of new and existing drugs with new indications used alone or in combination is increasing.
ObjectiveTo identify the advantages...
-
Where Do Real-Time Prescription Benefit Tools Fit in the Landscape of High US Prescription Medication Costs? A Narrative Review
The problem of unaffordable prescription medications in the United States is complex and can result in poor patient adherence to therapy, worse...
-
How the National Health Insurance Coverage policy changed the use of lenvatinib for adult patients with advanced hepatocellular carcinoma: a retrospective cohort analysis with real world big data
BackgroundTo establish a long-term mechanism to control the cost burden of drugs, the Chinese government organized seven rounds of price negotiations...
